Practice guideline for the treatment of patients with panic disorder

American Journal of Psychiatry

Volumn 155, Issue 5 SUPPL., 1998, Pages 1-34

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ANTICONVULSIVE AGENT; BENZODIAZEPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUSPIRONE; CALCIUM CHANNEL BLOCKING AGENT; CLONIDINE; INOSITOL; MONOAMINE OXIDASE INHIBITOR; NEFAZODONE; SEROTONIN UPTAKE INHIBITOR; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

AGE; CLINICAL FEATURE; CLINICAL TRIAL; COMORBIDITY; CULTURAL FACTOR; DISEASE COURSE; DRUG EFFICACY; HUMAN; MOOD; PANIC; PATIENT COMPLIANCE; PATIENT EDUCATION; PERSONALITY DISORDER; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSYCHOTHERAPY; REVIEW; SEX DIFFERENCE; SIDE EFFECT; SUBSTANCE ABUSE; SUICIDAL BEHAVIOR; TREATMENT OUTCOME; TREATMENT PLANNING;

ADOLESCENT; ADULT; AGED; CHILD; COMBINED MODALITY THERAPY; FEMALE; HUMANS; MALE; MIDDLE AGED; PANIC DISORDER; PSYCHOTHERAPY; PSYCHOTROPIC DRUGS;

EID: 0031941071     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (273)

1. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th ed (DSM-IV). Washington, DC, APA, 1994 [G]
2. Ballenger JC, Pecknold J, Rickels K, Sellers EM: Medication discontinuation in panic disorders. J Clin Psychiatry 1993; 54(Oct suppl): 15-21, discussion 22-24 [F]
3. Katschnig H, Amering M, Stolk JM, Ballenger JC: Predictors of quality of life in a long-term follow-up study of panic disorder patients after a clinical drug trial. Psychopharmacol Bull 1996; 32: 149-155 [C]
4. Roy-Byrne PP, Cowley DS: Course and outcome in panic disorder: a review of recent follow-up studies. Anxiety 1995; 1: 150-160 [F]
5. Weissman MM, Bland RC, Canino GJ, Faravelli C, Greenwald S, Hwu HG, Joyce PR, Karam EG, Lee CK, Lellouch J, Lepine JP, Newman SC, Oakley-Browne MA, Rubio-Stipec M, Wells JE, Wickramaratne PJ, Wittchen HA, Yeh EK: The cross-national epidemiology of panic disorder. Arch Gen Psychiatry 1997; 54: 305-309 [E]
6. Moreau D, Weissman MM: Panic disorder in children and adolescents: a review. Am J Psychiatry 1992; 149: 1306-1314 [F]
7. Lesser IM, Rubin RT, Rifkin RP, Swinson RP, Ballenger JC, Burrows GD, DuPont RL, Noyes R, Pecknold JC: Secondary depression in panic disorder and agoraphobia, II: dimensions of depression symptomatology and their response to treatment. J Affect Disord 1989; 16: 49-58 [B]
8. Klerman G, Weissman MM, Ouellette R, Johnson J, Greenwald S: Panic attacks in the community: social morbidity and health care utilization. JAMA 1991; 265: 742-746 [E]
9. Weissman MM, Klerman GL, Markowitz JS, Ouellette R: Suicidal ideation and attempts in panic disorder and attacks. N Engl J Med 1989; 321: 1209-1214 [C]
10. Markowitz JS, Weissman MM, Ouellette R, Lish JD, Klerman GL: Quality of life in panic disorder. Arch Gen Psychiatry 1989; 46: 984-992 [B]
11. Knowles JA, Weissman MM: Panic disorder and agoraphobia, in American Psychiatric Press Review of Psychiatry, vol 14. Edited by Oldham JM, Riba MB. Washington, DC, American Psychiatric Press, 1995, pp 383-404 [G]
12. Goldstein RB, Wickramarante PJ, Horwath E, Weissman MM: Familial aggregation and phenomenology of "early"-onset (at or before age 20 years) panic disorder. Arch Gen Psychiatry 1997; 54: 271-278 [C]
13. Kendler KS, Neale MC, Kessler RC, Heath AC, Eaves LJ: A test of the equal-environment assumption in twin studies of psychiatric illness. Behav Genet 1993; 23: 21-27 [D]
14. Kendler KS, Neale MC, Kessler RC, Heath AC, Eaves LJ: Panic disorder in women: a population-based twin study. Psychol Med 1993; 23: 387-406 [D]
15. American Psychiatric Association: Practice Guideline for Psychiatric Evaluation of Adults. Am J Psychiatry 1995; 152(Nov suppl): 63-80 [G]
16. Cross-National Collaborative Panic Study SPI: Drug treatment of panic disorder: comparative efficacy of alprazolam, imipramine, and placebo. Br J Psychiatry 1992; 160: 191-202, discussion 202-205; correction 1993; 161: 724 [A]
17. Barlow DH, Craske MG: Mastery of Your Anxiety and Panic II. Albany, NY, Graywind Publications, 1994 [G]
18. Lydiard RB, Morton WA, Emmanuel NP, Zealberg JJ, Laraia MT, Stuart GW, O'Neil PM, Ballenger JC: Preliminary report: placebo-controlled, double-blind study of the clinical and metabolic effects of desipramine in panic disorder. Psychopharmacol Bull 1993; 29: 183-188 [A]
19. Barlow DH, Craske MG, Cerney JA, Klosko JS: Behavioral treatment of panic disorder. Behavior Therapy 1989; 20: 261-282 [A]
20. Clark DM, Salkovskis PM, Hackmann A, Middleton H, Anastasiades P, Gelder M: A comparison of cognitive therapy, applied relaxation and imipramine in the treatment of panic disorder. Br J Psychiatry 1994; 164: 759-769 [A]
21. Beck AT, Sokol L, Clark DA, Berchick R, Wright F: A crossover study of focused cognitive therapy for panic disorder. Am J Psychiatry 1992; 149: 778-783 [A]
22. Lydiard RB, Lesser IM, Ballenger JC, Rubin RT, Laraia M, DuPont R: A fixed-dose study of alprazolam 2 mg, alprazolam 6 mg, and placebo in panic disorder. J Clin Psychopharmacol 1992; 12: 96-103 [A]
23. Fiegenbaum W: Long-term efficacy of ungraded versus graded massed exposure in agoraphobics, in Panic and Phobias 2: Treatments and Variables Affecting Course and Outcome. Edited by Hand I, Wittchen H-U. Berlin, Springer-Verlag, 1988, pp 83-88 [G]
24. Barlow DH: Anxiety and Its Disorders: The Nature and Treatment of Anxiety and Panic. New York, Guilford Press, 1988 [G]
25. Chambless DL, Gillis MM: Cognitive therapy of anxiety disorders. J Consult Clin Psychol 1993; 61: 248-260 [E]
26. Clum GA, Suris R: A meta-analysis of treatments for panic disorder. J Consult Clin Psychol 1993; 61: 317-326 [E]
27. Hofmann SG, Lehman CL, Barlow DH: How specific are specific phobias? J Behav Ther Exp Psychiatry 1997; 28: 233-240 [C]
28. Margraf J, Gobel M, Schneider S: Cognitive-Behavioral Treatments for Panic Disorder, vol 5. Amsterdam, Swets and Zeitlinger,1990[G]
29. Craske MG, Brown TA, Barlow DH: Behavioral treatment of panic disorder: a two-year follow-up. Behavior Therapy 1991; 22: 289-304 [D]
30. Klosko JS, Barlow DH, Tassinari R, Cerny JA: A comparison of alprazolam and behavior therapy in treatment of panic disorder. J Consult Clin Psychol 1990; 58: 77-84 [A]
31. Clark DB, Agras WS: The assessment and treatment of performance anxiety in musicians. Am J Psychiatry 1991; 148: 598-605 [A]
32. Black DW, Wesner R, Bowers W, Gabel J: A comparison of fluvoxamine, cognitive therapy and placebo in the treatment of panic disorder. Arch Gen Psychiatry 1993; 50: 44-50 [A]
33. Telch MJ, Lucas JA, Schmidt NB, Hanna HH, Jaimez LT, Lucas RA: Group cognitive-behavioral treatment of panic disorder. Behav Res Ther 1993; 31: 279-287 [A]
34. Craske MG, Rodriguez BI: Behavioral treatment of panic disorders and agoraphobia. Prog Behav Modif 1994; 29: 1-26 [A]
35. Shear MK, Pilkonis PA, Cloitre M, Leon AC: Cognitive behavioral treatment compared with nonprescriptive treatment of panic disorder. Arch Gen Psychiatry 1994; 51: 395-401 [A]
36. Ost LG, Westling BE: Applied relaxation vs cognitive behavior therapy in the treatment of panic disorder. Behav Res Ther 1995; 33: 145-158 [A]
37. Ost LG, Westling BE, Hellstrom K: Applied relaxation exposure in vivo and cognitive methods in the treatment of panic disorder with agoraphobia. Behav Res Ther 1993; 31: 383-394 [A]
38. van den Hout M, Arntz A, Hoekstra R: Exposure reduced agoraphobia but not panic and cognitive therapy reduced pain but not agoraphobia. Behav Res Ther 1994; 32: 447-451 [A]
39. Marks IM, Swinson RP, Basoglu M: Alprazolam and exposure alone and combined in panic disorder with agoraphobia. Br J Psychiatry 1993; 162: 776-787 [B]
40. Swinson RP, Soulios C, Cox BJ, Kuch K: Brief treatment of emergency room patients with panic attacks. Am J Psychiatry 1992; 149: 944-946 [A]
41. Swinson RP, Fergus KD, Cox BJ, Wickwire K: Efficacy of telephone-administered behavioral therapy for panic disorder. Behav Res Ther 1995; 33: 465-469 [B]
42. Fava GA, Zielezny M, Savron G, Grandi S: Long-term effects of behavioural treatment for panic disorder with agoraphobia. Br J Psychiatry 1995; 166: 87-92 [B]
43. Brown TA, Barlow DH: Long term outcome of cognitive behavioral treatment of panic disorder. J Consult Clin Psychol 1995; 63: 754-765 [B]
44. O'Sullivan G, Marks IM: Long-term outcome of phobic and obsessive compulsive disorders after exposure: a review chapter, in The Treatment of Anxiety: Handbook of Anxiety, vol 4. Edited by Noyes R, Roth M, Burrows G. Amsterdam, Elsevier, 1990, pp 82-108 [G]
45. Barlow DH: Cognitive-behavioral therapy for panic disorder: current status. J Clin Psychiatry 1997; 58(suppl 2): 32-36 [F]
46. Shear MK, Barlow D, Gorman J, Woods S; Multicenter treatment study of panic disorder. Presented at the 36th annual meeting of the American College of Neuropsychopharmacology, Kamuela, Hawaii, Dec 8-12, 1997 [A]
47. Neron S, Lacroix D, Chaput Y: Group vs individual cognitive behaviour therapy in panic disorder: an open clinical trial with a six month follow-up. Can J Behavioral Sci 1995; 27: 379-392 [C]
48. Cerny JA, Barlow DH, Craske MG, Himadi WG: Couples treatment of agoraphobia: a two-year follow-up. Behavior Therapy 1987; 18: 401-415 [C]
49. Craske MG, Rowe M, Lewin M, Noriega-Dimitri R: Interoceptive exposure versus breathing retraining within cognitive-behavioural therapy for panic disorder with agoraphobia. Br J Clin Psychol 1997; 36(part 1): 85-99 [A]
50. Hoffart A, Thornes K, Hedley LM: DSM-III-R axis I and II disorders in agoraphobic inpatients before and after psychosocial treatment. Psychiatry Res 1995; 56: 1-9 [C]
51. Lidren D, Warkins P, Gould R, Clum G, Asterino M, Tulloch H: A comparison of bibliotherapy and group therapy in the treatment of panic disorder. J Consult Clin Psychol 1994; 62: 865-869 [B]
52. Carter MM, Turovsky J, Barlow DH: Interpersonal relationships in panic disorder with agoraphobia: a review of empirical evidence. Clin Psychol: Science and Practice 1994; 1: 25-34 [F]
53. Spiegel DA, Bruce TJ, Gregg SF, Nuzzarello A: Does cognitive behavior therapy assist slow-taper alprazolam discontinuation in panic disorder? Am J Psychiatry 1994; 151: 876-881 [A]
54. Otto MW, Pollack MH, Sachs GS, Reiter SR, Meltzer-Brody S, Rosenbaum JF: Discontinuation of benzodiazepine treatment: efficacy of cognitive-behavioral therapy for patients with panic disorder. Am J Psychiatry 1993; 150: 1485-1490 [A]
55. Spiegel DA, Bruce TJ: Benzodiazepines and exposure-based cognitive behavior therapies for panic disorder: conclusion from combined treatment trials. Am J Psychiatry 1997; 154: 773-781 IF]
56. Milrod B, Busch F, Cooper A, Shapiro T: Manual of Panic-Focused Psychodynamic Psychotherapy. Washington, DC, American Psychiatric Press, 1997 [G]
57. Kohut H: Thoughts on narcissism and narcissistic rage. Psychoanal Study Child 1972; 27: 360-400 [G]
58. Bash M: Doing Brief Psychotherapy. New York, Basic Books, 1995 [G]
59. Gray JA: The neuropsychiatry of anxiety. Br J Psychol 1978; 69: 417-434 [G]
60. Sifneos PE: The current status of individual short-term dynamic psychotherapy and its future: an overview. Am J Psychother 1984; 38: 472-483 [G]
61. Sifneos PE: Short-term dynamic psychotherapy for patients with physical symptomatology. Psychother Psychosom 1984; 42: 48-51 [F]
62. Shear MK: Psychotherapeutic issues in long-term treatment of anxiety disorder patients. Psychiatr Clin North Am 1995; 18: 885-894 [F]
63. Wiborg IM, Dahl AA: Does brief dynamic psychotherapy reduce the relapse rate of panic disorder? Arch Gen Psychiatry 1996; 53: 689-694 [A]
64. Beitman BD, Goldfried MR, Norcross JC: The movement toward integrating the psychotherapies: an overview. Am J Psychiatry 1989; 146: 138-147 [G]
65. Shear MK, Weiner K: Psychotherapy for panic disorder. J Clin Psychiatry 1997; 58(suppl 2): 38-43 [G]
66. Zitrin CM, Klein DF, Woerner MG: Treatment of agoraphobia with group exposure in vivo and imipramine. Arch Gen Psychiatry 1980; 37: 63-72 [A]
67. Zitrin CM, Klein DF, Woerner MG, Ross DC: Treatment of phobias, I: comparison of imipramine hydrochloride and placebo. Arch Gen Psychiatry 1983; 40: 125-138 [A]
68. Marks IM, Gray S, Cohen D, Hill R, Mawson D, Ramm E, Stern RS: Imipramine and brief therapist-aided exposure in agoraphobics having self-exposure homework. Arch Gen Psychiatry 1983; 40: 153-162 [A]
69. Mavissakalian M, Michelson L, Dealy RS: Pharmacological treatment of agoraphobia: imipramine vs imipramine with programmed practice. Br J Psychiatry 1983; 143: 348-355 [A]
70. Telch MJ, Agras WS, Taylor CB, Roth WT, Gallen CC: Combined pharmacological and behavioral treatment for agoraphobia, Behav Res Ther 1985; 23: 325-335 [A]
71. Mavissakalian M, Michelson L: Relative and combined effectiveness of therapist-assisted in vivo exposure and imipramine. J Clin Psychiatry 1986; 47: 117-122 [B]
72. Mavissakalian M, Michelson L: Two-year follow-up of exposure and imipramine treatment of agoraphobia. Am J Psychiatry 1986; 143: 1106-1112 [B]
73. Oehrberg S, Christiansen PE, Behnke K: Paroxetine in the treatment of panic disorder: a randomized double-blind placebocontrolled study. Br J Psychiatry 1995; 167: 374-379 [A]
74. Pollack MH, Otto MW, Kaspi SP, Hammerness PG, Rosenbaum JF: Cognitive behavior therapy for treatment-refractory panic disorder. J Clin Psychiatry 1994; 55: 200-205 [B]
75. Nagy LM, Krystal JH, Woods SW: Clinical and medication outcome after short-term alprazolam and behavioral group treatment of panic disorder: 2.5 year naturalistic follow-up. Arch Gen Psychiatry 1989; 46: 993-999 [B, C]
76. Kabat-Zinn J, Massion AO, Kristeller J, Peterson LG, Fletcher KE, Pbert L, Lenderking WR, Santorelli SF: Effectiveness of a meditation-based stress reduction program in the treatment of anxiety disorders. Am J Psychiatry 1992; 149: 936-943 [B]
77. Miller JJ, Fletcher K, Kabat-Zinn J: Three-year follow-up and clinical implications of a mindfulness meditation-based stress reduction intervention in the treatment of anxiety disorders. Gen Hosp Psychiatry 1995; 17: 192-200 [D]
78. Buglass D, Clarke J, Henderson AS, Kreitman N: A study of agoraphobic housewives. Psychol Med 1977; 7: 73-86 [D]
79. Arrindell WA, Emmelkamp PM: Marital adjustment, intimacy and needs in female agoraphobics and their partners: a controlled study. Br J Psychiatry 1986; 149: 592-602; correction 1987; 150: 273 [D]
80. Lange A, van Dyck R: The function of agoraphobia in the marital relationship. Acta Psychiatr Scand 1992; 85: 89-93 [E]
81. Hafner RJ: Predicting the effects on husbands of behaviour therapy for wives' agoraphobia. Behav Res Ther 1984; 22: 217-226 [C]
82. Milton F, Hafner J: The outcome of behavior therapy for agoraphobia in relation to marital adjustment. Arch Gen Psychiatry 1979; 36: 807-811 [B]
83. Jacobson NS, Holtzworth-Monroe A, Schmaling KB: Marital therapy and spouse involvement in the treatment of depression, agoraphobia, and alcoholism. J Consult Clin Psychol 1989; 57: 5-10 [F]
84. Himadi WG, Cerny JA, Barlow DH, Cohen S, O'Brien GT: The relationship of marital adjustment to agoraphobia treatment outcome. Behav Res Ther 1986; 24: 107-115 [C]
85. Barlow DH, O'Brien GT, Last CG: Couples treatment of agoraphobia. Behavior Therapy 1984; 15: 41-58 [C]
86. Arnow BA, Taylor CB, Agras WS: Enhancing agoraphobia treatment outcome by changing couple communication patterns. Behavior Therapy 1985; 16: 452-467 [C]
87. Lydiard RB, Pollack MH, Judge R, Michelson D, Tamura R: Fluoxetine in panic disorder: a placebo-controlled study. Presented at the 10th Congress of the European College of Neuropsychopharmacology, Vienna, Sept 13-17, 1997 [A]
88. Gorman JM, Liebowitz MR, Fyer AJ, Goetz D, Campeas RB, Fyer MR, Davies SO, Klein DF: An open trial of fluoxetine in the treatment of panic disorder. J Clin Psychopharmacol 1987; 7: 319-332 [B]
89. Schneier FR, Liebowitz MR, Davies SO, Fairbanks J, Hollander E, Campeas R, Klein DF: Fluoxetine in panic disorder. J Clin Psychopharmacol 1990; 10: 119-121 [B]
90. Wolkow R, Apter J, Clayton A, Coryell W, Cunningham L, McEntee W, O'Hair D, Pollack M, Rausch J, Stewart R, Weisler R: Double-blind flexible dose study of sertraline and placebo in patients with panic disorder. Presented at the XX Congress of the Collegium Internationale Neuro-Psychopharmacologicum, Melbourne, Australia, June 23-27, 1996 [A]
91. Baumel B, Bielski R, Carman J, Hegel M, Houck C, Linden R, Nakra B, Ota K, Pohl R, Wolkow R: Double-blind comparison of sertraline and placebo in patients with panic disorder. Ibid [A]
92. Ballenger JC, Wheadon DE, Steiner M, Bushnell W, Gergel IP: Double-blind, fixed-dose, placebo-controlled study of paroxetine in the treatment of panic disorder. Am J Psychiatry 1998; 155: 36-42 [A]
93. LeCrubier Y, Bakker A, Dunbar G, Judge R: A comparison of paroxetine, clomipramine and placebo in the treatment of panic disorder. Acta Psychiatr Scand 1997; 95: 145-152 [A]
94. Hoehn-Saric R, McLeod DR, Hipsley PA: Effect of fluvoxamine on panic disorder. J Clin Psychopharmacol 1993; 13: 321-326 [B]
95. de Beurs E, van Balkom AJ, Lange A, Koele P, van Dyck R: Treatment of panic disorder with agoraphobia: comparison of fluvoxamine, placebo, and psychological panic management combined with exposure and of exposure in vivo alone. Am J Psychiatry 1995; 152: 683-691 [B]
96. Westenberg HG, den Boer JA: Selective monoamine uptake inhibitors and a serotonin antagonist in the treatment of panic disorder. Psychopharmacol Bull 1989; 25: 119-123 [B]
97. Wade AG, Lepola U, Koponen HJ, Pedersen V, Pedersen T: The effect of citalopram in panic disorder. Br J Psychiatry 1997; 170: 549-553 [A]
98. Boyer W: Serotonin uptake inhibitors are superior to imipramine and alprazolam in alleviating panic attacks: a meta-analysis. Int Clin Psychopharmacol 1995; 10: 45-49 [E]
99. Lejoyeux M, Ades J: Antidepressant discontinuation: a review of the literature. J Clin Psychiatry 1997; 58 (July suppl): 11-16 [G]
100. Louie AK, Lewis TB, Lannon RA: Use of low-dose fluoxetine in major depression and panic disorder. J Clin Psychiatry 1993; 54: 435-438 [C]
101. Emmanuel NP, Crosby C, Ware MR, Lydiard RB: The efficacy of once-a-week fluoxetine dosing in the treatment of panic disorder, in 1996 Annual Meeting New Research Program and Abstracts. Washington, DC, American Psychiatric Association, 1996, p 252 [G]
102. DuBoff E, England D, Ferguson JM, Londborg PD, Rosenthal MH, Smith W, Weise C, Wolkow RM: Sertraline in the treatment of panic disorder. Presented at the 8th Congress of the European College of Neuropsychopharmacology, Venice, Sept 30 to Oct 4, 1995 [A]
103. Gergel I, Burnham D, Kumar R: Treatment of panic disorder with paroxetine. Presented at the 6th World Congress of Biological Psychiatry, Nice, France, June 22-27, 1997 [A]
104. Klein D: Delineation of two drug-responses for anxiety syndromes. Psychopharmacologia 1964; 5: 397-408 [A]
105. Uhlenhuth EH, Matuzas W, Glass RM, Easton C: Response of panic disorder to fixed doses of alprazolam or imipramine. J Affect Disord 1989; 17: 261-270 [A]
106. Modigh K, Westberg P, Eriksson E: Superiority of clomipramine over imipramine in the treatment of panic disorder: a placebocontrolled trial. J Clin Psychopharmacol 1992; 12: 251-261 [A]
107. Andersch S, Rosenberg NK, Kullingsjo H, Ottoson JQ, Hanson L, Lorentzen K, Mellergard M, Rasmussen S, Rosenberg R: Efficacy and safety of alprazolam, imipramine, and placebo in treating panic disorder: a Scandinavian multicenter study. Acta Psychiatr Scand Suppl 1991; 365: 18-27 [A]
108. Mavissakalian M, Perel J: Imipramine in the treatment of agoraphobia: dose-response relationships. Am J Psychiatry 1985; 142: 1032-1036 [A]
109. Mavissakalian MR, Perel JM: Imipramine dose-response relationship in panic disorder with agoraphobia. Arch Gen Psychiatry 1989; 46: 127-131 [A]
110. Mavissakalian MR, Perel JM: Imipramine treatment of panic disorder with agoraphobia: dose ranging and plasma level-response relationships. Am J Psychiatry 1995; 152: 673-682 [A]
111. Maier W, Roth SM, Argyle N, Buller R, Lavori P, Brandon S, Benkert O: Avoidance behaviour: a predictor of the efficacy of pharmacotherapy in panic disorder? Eur Arch Psychiatry Clin Neurosci 1991; 241: 151-158 [A]
112. Cassano GB, Toni C, Musetti L: Treatment of panic disorder, in Synaptic Transmission. Edited by Biggio G, Concas A, Costa E. New York, Raven Press, 1992, pp 449-461 [A]
113. Curtis GC, Massana J, Udina C, Ayuso JL, Cassano GB, Perugi G: Maintenance drug therapy of panic disorder. J Psychiatr Res 1993;27(suppl 1): 127-142 [A]
114. Keller MB, Lavori PW, Goldenberg IM, Baker LA, Pollack MH, Sachs GS, Rosenbaum JF, Deltito JA, Leon A, Shear K, Klerman GL: Influence of depression on the treatment of panic disorder with imipramine, alprazolam, imipramine. J Affect Disord 1993; 28: 27-38 [A]
115. Woods S, Nagy LM, Koleszar AS, Krystal JH, Heninger GR, Charney DS: Controlled trial of alprazolam supplementation during imipramine treatment of panic disorder. J Clin Psychopharmacol 1991; 12: 32-38 [A]
116. Mellergard M, Lorentzen K, Bech P, Ottoson JQ, Rosenberg R: A trend analysis of changes during treatment of panic disorder with alprazolam and imipramine. Acta Psychiatr Scand Suppl 1991; 365: 28-32 [A]
117. Pollack MH, Otto MW, Sachs GS, Leon A, Shear MK, Deltito JA, Keller MB, Rosenbaum JF: Anxiety psychopathology predictive of outcome in patients with panic disorder and depression treated with imipramine, alprazolam, and placebo. J Affect Disord 1994; 30: 273-281 [A]
118. Den Boer JA, Westenberg HG: Effect of a serotonin and noradrenaline uptake inhibitor in panic disorder: a double-blind comparative study with fluvoxamine and maprotiline. Int Clin Psychopharmacol 1988; 3: 59-74 [B]
119. Cassano GB, Petracca A, Perugi G, Nisita C, Musetti L, Mengali F, McNair DM: Clomipramine for panic disorder, I: the first 10 weeks of a long-term comparison with imipramine. J Affect Disord 1988; 14: 123-127 [B]
120. Monteiro WO, Noshirvani HF, Marks IM: Anorgasmia from clomipramine in obsessive-compulsive disorder: a controlled trial. Br J Psychiatry 1987; 151: 107-112 [B]
121. Mavissakalian M, Perel JM: Clinical experiments in maintenance and discontinuation of imipramine therapy in panic disorder with agoraphobia. Arch Gen Psychiatry 1992; 49: 318-323 [B]
122. Mavissakalian M, Perel JM: Protective effects of imipramine maintenance treatment in panic disorder with agoraphobia. Am J Psychiatry 1992; 149: 1053-1057 [B]
123. Sheehan DV: Tricyclic antidepressants in the treatment of panic and anxiety disorders. Psychosomatics 1986; 27: 10-16 [F]
124. Fyer AJ, Liebowitz MR, Gorman JM, Campeas R, Levin A, Davies SO, Goetz D, Klein DF: Discontinuation of alprazolam treatment in panic patients. Am J Psychiatry 1987; 144: 303-308 [B]
125. Klerman GL: Overview of the Cross-National Collaborative Panic Study. Arch Gen Psychiatry 1988; 45: 407-412 [F]
126. Dunner DL, Ishiki D, Avery DH, Wilson LG, Hyde TS: Effect of alprazolam and diazepam in anxiety and panic attacks in panic disorder: a controlled study. J Clin Psychiatry 1986; 47-458-460 [B]
127. Ballenger JC, Burrows GD, DuPont RL Jr, Lesser IM, Noyes R Jr, Pecknold JC, Rifkin A, Swinson RP: Alprazolam in panic disorder and agoraphobia: results from a multicenter trial, I: efficacy in short-term treatment. Arch Gen Psychiatry 1988; 45: 413-422 [A]
128. Tesar GE, Rosenbaum JF, Pollack MH, Otto MW, Sachs GS, Herman JB, Cohen LS, Spier SA: Double-blind, placebo-controlled comparison of clonazepam and alprazolam for panic disorder. J Clin Psychiatry 1991; 52: 69-76 [A]
129. Schweizer E, Rickels K, Weiss S, Zavodnick S: Maintenance drug treatment of panic disorder, I: results of a prospective, placebo-controlled comparison of alprazolam and imipramine. Arch Gen Psychiatry 1993; 50: 51-60 [A]
130. Dager SR, Roy-Byrne P, Hendrickson H, Cowley DS, Avery DH, Hall KC, Dunner DL: Long-term outcome of panic states during double-blind treatment and after withdrawal of alprazolam and placebo. Ann Clin Psychiatry 1992; 4: 251-258 [A]
131. Chouinard G, Annable L, Fontaine R, Solyom L: Alprazolam in the treatment of generalized anxiety and panic disorders: a double-blind placebo-controlled study. Psychopharmacology (Berl) 1982; 77: 229-233 [B]
132. McNair DM, Kahn RJ: Imipramine compared with a benzodiazepine for agoraphobia, in Anxiety: New Research and Changing Concepts. Edited by Klein DF, Rabkin J. New York, Raven Press, 1981, pp 69-80 [B]
133. Noyes RJ, Anderson DJ, Clancy J, Crowe RR, Slymen DJ, Ghoneim MM, Hinrichs JV: Diazepam and propranolol in panic disorder and agoraphobia. Arch Gen Psychiatry 1984; 41: 287-292 [A]
134. Schweizer E, Rickeis K: Failure of buspirone to manage benzodiazepine withdrawal. Am J Psychiatry 1986; 143: 1590-1592 [B]
135. Schweizer E, Case WG, Rickeis K: Benzodiazepine dependence and withdrawal in elderly patients. Am J Psychiatry 1989; 146: 529-531 [B]
136. Schweizer E, Clary C, Dever AI, Mandos LA: The use of low-dose intranasal midazolam to treat panic disorder: a pilot study. J Clin Psychiatry 1992; 53: 19-22 [B]
137. Charney DS, Woods SW: Benzodiazepine treatment of panic disorder: a comparison of alprazolam and lorazepam. J Clin Psychiatry 1989; 50: 418-423 [B]
138. Pyke RE, Greenberg HS: Double-blind comparison of alprazolam and adinazolam for panic and phobia disorders. J Clin Psychopharmacol 1989; 9: 15-21 [B]
139. Savoldi F, Somenzini G, Ecari U: Etizolam versus placebo in the treatment of panic disorder with agoraphobia: a double-blind study. Curr Med Res Opin 1990; 12: 185-190 [A]
140. Beaudry P, Fontaine R, Chouinard G: Bromazepam, another high-potency benzodiazepine for panic attacks (letter). Am J Psychiatry 1984; 141: 464-465 [G]
141. Noyes R, Borrows GD, Reich JH, Judd FK, Garvey M, Morman TR, Cook BL, Marriot P: Diazepam versus alprazolam for the treatment of panic disorder. J Clin Psychiatry 1996; 57: 349-355 [A]
142. Benzodiazepine Dependence, Toxicity, and Abuse: A Task Force Report of the American Psychiatric Association. Washington, DC, APA, 1990 [G]
143. Rickels K, Schweizer E, Weiss S, Zavodnick S: Maintenance drug treatment for panic disorder, II: short- and long-term outcome after drug taper. Arch Gen Psychiatry 1993; 50: 61-68 [B]
144. Klein E, Colin V, Stolk J, Lenox RH: Alprazolam withdrawal in patients with panic disorder and generalized anxiety disorder: vulnerability and effect of carbamazapine. Am J Psychiatry 1994; 151: 1760-1766 [A]
145. Noyes R Jr, Garvey MJ, Cook B, Suelzer M: Controlled discontinuation of benzodiazepine treatment for patients with panic disorder. Am J Psychiatry 1991; 148: 517-523 [B]
146. Pecknold JC, Swinson RP: Taper withdrawal studies with alprazolam inpatients with panic disorder and agoraphobia. Psychopharmacol Bull 1986; 22: 173-176 [A]
147. Rosenbaum JF, Moroz G, Bowden CL: Clonazepam in the treatment of panic disorder with or without agoraphobia: a dose-response study of efficacy, safety, and discontinuance. J Clin Psychopharmacol 1997; 17: 390-400 [A]
148. Lesser IM, Lydiard RB, Antal E, Rubin RT, Ballenger JC, DuPont R: Alprazolam plasma concentrations and treatment response in panic disorder and agoraphobia. Am J Psychiatry 1992; 149: 1556-1562 [A]
149. Greenblatt DJ, Harmatiz JS, Shader RI: Plasma alprazolam concentrations: relation to efficacy and side effects in the treatment of panic disorder. Arch Gen Psychiatry 1993; 50: 715-722 [B]
150. Lepola UM, Rimon RH, Riekkinen PJ: Three-year follow-up of patients with panic disorder after short-term treatment with alprazolam and imipramine. Int Clin Psychopharmacol 1993; 8: 115-118 [B]
151. Sheehan DV, Claycomb JB, Kouretas N: Monoamine oxidase inhibitors: prescription and patient management. Int J Psychiatry Med 1980-1981; 10: 99-121 [G]
152. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 2nd ed (DSM-II). Washington, DC, APA, 1968 [G]
153. Bakish D, Saxena BM, Bowen R, D'Souza J: Reversible monoamine oxidase-A inhibitors in panic disorder. Clin Neuropsychopharmacol 1993; 16(suppl 2): S77-S82 [A]
154. Garcia-Borreguero D, Lauer CJ, Ozdaglar A, Wiedemann K, Holsboer F, Krieg JC: Brofaromine in panic disorder: a pilot study with a new reversible inhibitor of monoamine oxidase-A. Pharmacopsychiatry 1992; 25: 261-264 [B]
155. van Harten J: Clinical pharmacokinetics of selective serotonin reuptake inhibitors. Clin Pharmacokinet 1993; 24: 203-220 [F]
156. Pollack MH, Worthington JJ, Otto MW, Maki KM, Smoller JW, Manfro GG, Rudolph R, Rosenbaum JF: Venlafaxine for panic disorder: results from a double-blind, placebo-controlled study. Psychopharmacol Bull 1996; 32: 667-670 [A]
157. Geracioti JD: Venlafaxine treatment of panic disorder: a case series. J Clin Psychiatry 1995; 56: 408-410 [G]
158. Charney DS, Woods SW, Goodman WK, Rifkin B, Kinch M, Aiken B, Quadrino LM, Heninger GR: Drug treatment of panic disorder: the comparative efficacy of imipramine, alprazolam, and trazodone. J Clin Psychiatry 1986; 47: 580-586 [B]
159. Mavissakalian M, Perel J, Bowler K, Dealy R: Trazodone in the treatment of panic disorder and agoraphobia with panic attacks. Am J Psychiatry 1987; 144: 785-787 [B]
160. Sheehan DV, Davidson J, Manschreck T, Van Wyck Fleet Ji Lack of efficacy of a new antidepressant (bupropion) in the treatment of panic disorder with phobias. J Clin Psychopharmacol 1983; 3: 28-31 [G]
161. Zajecka JM: The effect of nefazodone on comorbid anxiety symptoms associated with depression: experience in family practice and psychiatric outpatient settings. J Clin Psychiatry 1996; 57 (2 suppl): 10-14 [A]
162. DeMartinis NA, Schweizer E, Rickels K: An open-label trial of nefazodone in high comorbidity panic disorder. J Clin Psychiatry 1996; 57: 245-248 [B]
163. Keck PE Jr, McElroy SL, Friedman LM: Valproate and carbamazepine in the treatment of panic and posttraumatic stress disorders, withdrawal states, and behavioral dyscontrol syndromes. J Clin Psychopharmacol 1992; 12(1 suppl): 36S-41S [F]
164. Uhde TW, Stein MB, Post RM: Lack of efficacy of carbamazepine in the treatment of panic disorder. Am J Psychiatry 1988; 145: 1104-1109 [B]
165. Lum M, Fontaine R, Elie R, Ontiveros A: Divalproex sodium's antipanic effect in panic disorder: a placebo-controlled study. Biol Psychiatry 1990; 27(9A): 164A [A, B]
166. Woodman CL, Noyes R: Panic disorder: treatment with valproate. J Clin Psychiatry 1994; 55: 134-136 [B]
167. Munjack DJ, Crocker B, Cabe D, Brown R, Usigli R, Zulueta A, McManus M, McDowell D, Palmer R, Leonard M: Alprazolam, propranolol, and placebo in the treatment of panic disorder and agoraphobia with panic attacks. J Clin Psychopharmacol 1989; 9: 22-27 [A]
168. Ravaris CL, Friedman MJ, Hauri PJ, McHugo GJ: A controlled study of alprazolam and propranolol in panic-disordered and agoraphobic outpatients. J Clin Psychopharmacol 1991; 11: 344-350 [A]
169. Shehi M, Patterson WM: Treatment of panic attacks with alprazolam and propranolol. Am J Psychiatry 1984; 141: 900-901 [B]
170. Klein E, Uhde TW: Controlled study of verapamil for treatment of panic disorder. Am J Psychiatry 1988; 145: 431-434 [A]
171. Benjamin J, Levine J, Fux M, Aviv A, Levy D, Belmaker RH: Double-blind, placebo-controlled, crossover trial of inositol treatment for panic disorder. Am J Psychiatry 1995; 152: 1084-1086 [A]
172. Uhde TW, Stein MB, Vittone BJ, Siever LJ, Boulenger JP, Klein E, Mellman TA: Behavioral and physiologic effects of short-term and long-term administration of clonidine in panic disorder. Arch Gen Psychiatry 1989; 46: 170-177 [A, B]
173. Spielberger CD: State-Trait Anxiety Inventory. Palo Alto, Calif, Consulting Psychologists Press, 1985 [G]
174. Zung WWK: A rating instrument for anxiety disorders. Psychosomatics 1971; 12: 371-379 [G]
175. Hoehn-Saric R, Merchant AF, Keyser ML, Smith VK: Effects of clonidine on anxiety disorders. Arch Gen Psychiatry 1981; 38: 1278-1282 [B]
176. Sheehan DV, Raj AB, Harnett-Sheehan K, Soto S, Knapp E: The relative efficacy of high-dose buspirone and alprazolam in the treatment of panic disorder: a double-blind placebo-controlled study. Acta Psychiatr Scand 1993; 88: 1-11 [A]
177. Sheehan DV, Raj A, Sheehan KH, Soto S: Is buspirone effective for panic disorder? J Clin Psychopharmacol 1990; 10: 3-11 [A]
178. Pollard CA: Inpatient treatment of complicated agoraphobia and panic disorder. Hosp Community Psychiatry 1987; 38: 951-958 [B]
179. Pollard HJ, Pollard CA: Follow-up study of an inpatient program for complicated agoraphobia and panic disorder. Anxiety Disorders Practice J 1993; 1: 37-40 [C]
180. Cottraux J, Note ID, Cungi C, Legeron P, Heim F, Chneiweiss L, Bernard G, Bouvard M: A controlled study of cognitive behaviour therapy with buspirone or placebo in panic disorder with agoraphobia. Br J Psychiatry 1995; 167: 635-641 [A]
181. Wolfe BE, Maser JD (eds): Treatment of Panic Disorder: A Consensus Development Conference, Washington, DC, American Psychiatric Press, 1994 [G]
182. Coryell W, Noyes R, Clancy J: Excess mortality in panic disorder. Arch Gen Psychiatry 1982; 39: 701-703 [D]
183. Noyes R: Suicide and panic disorder: a review. J Affect Disord 1991; 22: 1-11 [F]
184. Warshaw MG, Massion AO, Peterson LG, Pratt LA, Keller MB: Suicidal behavior in inpatients with panic disorder: retrospective and prospective data. J Affect Disord 1995; 34: 235-247 [C, D]
185. Lepine JP, Chignon M, Teherani M: Suicide attempts in patients with panic disorder. Arch Gen Psychiatry 1993; 50: 144-149 [D]
186. Johnson J, Weissman MM, Klerman GL: Panic disorder comorbidity and suicide attempts. Arch Gen Psychiatry 1990; 47: 805-808 [D]
187. Beck AT, Steer RA, Snaderson WC, Skeie TM: Panic disorder and suicidal ideation and behavior; discrepant findings in psychiatric outpatients. Am J Psychiatry 1991; 148: 1195-1199 [D]
188. Hornig CD, McNally RJ: Panic disorder and suicide attempt: a reanalysis of data from the Epidemiologie Catchment Area study. Br J Psychiatry 1995; 167: 76-79 [D]
189. Fawcett J, Scheftner WA, Fogg L, Clark DC, Young MA, Hedeker D, Gibbons R: Time-related predictors of suicide in major affective disorder. Am J Psychiatry 1990; 147: 1189-1194 [C]
190. Mannuzza S: Panic disorder and suicide attempts. J Anxiety Disorders 1992; 6: 261-274 [D]
191. Cox BJ, Direnfeld DM, Swinson RP, Norton GR: Suicidal ideation and suicide attempts in panic disorder and social phobia. Am J Psychiatry 1994; 151: 882-887 [D]
192. Friedman S, Jones JC, Chernen L, Barlow DH: Suicidal ideation and suicide attempts among patients with panic disorder: a survey of two outpatient clinics. Am J Psychiatry 1992; 149: 680-685 [D]
193. Kushner MG, Sher KJ, Beitman BD: The relation between alcohol problems and the anxiety disorders. Am J Psychiatry 1990; 147: 685-695 [F]
194. Anthony JC, Tien AY, Petronis KR: Epidemiological evidence on cocaine use and panic attacks. Am J Epidemiol 1989; 129: 543-549 [C]
195. Mirin SM, Weiss RD, Griffin ML, Michael JL: Psychopathology in drug users and their families. Compr Psychiatry 1991; 32: 36-51 [E]
196. Nunes E, Quitkin B, Berman C: Panic disorder and depression in female alcoholics. J Clin Psychiatry 1988; 49: 441-443 [F]
197. Aronson TA, Craig TJ: Cocaine precipitation of panic disorder. Am J Psychiatry 1986; 143: 643-645 [D]
198. Pallanti S, Mazzi D: MDMA (Ecstasy) precipitation of panic disorder. Biol Psychiatry 1992; 32: 91-95 [G]
199. Moran C: Depersonalization and agoraphobia associated with marijuana use. Br J Med Psychol 1986; 59: 187-196 [B]
200. Cowley DS: Alcohol abuse, substance abuse, and panic disorder. Am J Med 1992;92(suppl 1A): 41S-48S [F]
201. Brown SA, Irwin M, Schuckit MA: Changes in anxiety among abstinent male alcoholics. J Stud Alcohol 1991; 52: 55-61 [B]
202. Thevos AK, Johnston AL, Latham PK, Randall CL, Adinoff B, Malcolm R: Symptoms of anxiety in inpatient alcoholics with and without DSM-III-R anxiety diagnoses. Alcohol Clin Exp Res 1991; 15: 102-105 [B]
203. George DT, Nutt DJ, Dwyer BA, Linnoila M: Alcoholism and panic disorder: is the comorbidity more than coincidence? Acta Psychiatr Scand 1990; 81: 97-107 [F]
204. Cox BJ, Norton GR, Swinson RP, Endler NS: Substance abuse and panic-related anxiety: a critical review. Behav Res Ther 1990; 28: 385-393 [E]
205. Anthenelli RM, Schuckit MA: Affective and anxiety disorders and alcohol and drug dependence: diagnosis and treatment. J Addict Dis 1993; 12: 73-87 [F]
206. Tucker P, Westermeyer J: Substance abuse in patients with comorbid anxiety disorder. Am J Addictions 1995; 4: 226-233 [C]
207. Westermeyer J, Tucker P: Comorbid anxiety disorder and substance disorder. Am J Addictions 1995; 4: 97-106 [C]
208. Ciraulo DA, Sands BF, Shader RI: Critical review of liability for benzodiazepine abuse among alcoholics. Am J Psychiatry 1988; 145: 1501-1506 [F]
209. Shelton RC, Harvey DS, Stewart PM, Loosen PT: Alprazolam in panic disorder: a retrospective analysis. Prog Neuropsychopharmacol Biol Psychiatry 1993; 17: 423-434 [E]
210. Lucas PB, Pickar D, Kelsoe J, Rapaport M, Pato C, Hommer D: Effects of the acute administration of caffeine in patients with schizophrenia. Biol Psychiatry 1990; 28: 35-40 [B]
211. Leibenluft E, Fiero PL, Bartko JJ, Moul DE, Rosenthal NE: Depressive symptoms and the self-reported use of alcohol, caffeine, and carbohydrates in normal volunteers and four groups of psychiatric outpatients. Am J Psychiatry 1993; 150: 294-301 [E]
212. Boulenger J-P, Uhde TW, Wolff EA, Post RM: Increased sensitivity to caffeine in patients with panic disorder. Arch Gen Psychiatry 1984; 41: 1067-1071 [D]
213. Bowen R, South M, Hawkes J: Mood swings in patients with panic disorder. Can J Psychiatry 1994; 39: 91-94 [G]
214. Savino M, Perugi G, Simonini E, Soriani A, Cassano GB, Akiskal HS: Affective comorbidity in panic disorder: is there a bipolar connection? J Affect Disord 1993; 28: 155-163 [D, G]
215. Marks IM: Fears, Phobias, and Rituals. New York, Oxford University Press, 1987 [G]
216. Marks IM: Agoraphobia, panic disorder and related conditions in the DSM-IIIR and ICD-10. J Psychopharmacol 1987; 1: 6-12 [G]
217. Herve C, Gaillard M, Roujas F, Huguenard P: Alcoholism in polytrauma. J Trauma 1986; 26: 1123-1126 [E]
218. Boudewyns PA, Woods MG, Hyer L, Albrecht JW: Chronic combat-related PTSD and concurrent substance abuse: implications for treatment of this frequent "dual diagnosis." J Traurm Stress 1991; 4: 549-560 [D]
219. Davidson J, Kudler H, Smith R: Treatment of posttraumatic stress disorder with amitriptyline and placebo. Arch Gen Psychiatry 1990; 47: 259-266 [A]
220. Davidson JR, Kudler HS, Saunders WB, Smith RD: Sympton and comorbidity patterns in World War II and Vietnam veter ans with posttraumatic stress disorder. Compr Psychiatry 1990; 31: 162-170 [D]
221. Pitman RK, Altman B, Greenwald E: Psychiatric complications during flooding therapy for posttraumatic stress disorder. J Clin Psychiatry 1991; 52: 17-20 [G]
222. Dansky BS, Roitzsch JC, Brady KT, Saladin ME: Posttraumatic stress disorder and substance abuse: use of research in a clinical setting. J Trauma Stress 1997; 10: 141-148 [C]
223. Cottier LB, Compton WM III, Mager D, Spitznagel EL, Janca A: Posttraumatic stress disorder among substance users from the general population. Am J Psychiatry 1992; 149: 664-670 [E]
224. Greist JH, Jefferson JW: Panic Disorder and Agoraphobia: A Guide, 2nd revised ed. Middleton, Wis, Dean Foundation for Health, Research, and Education, 1993 [G]
225. Mavissakalian M: The relationship between panic disorder/agoraphobia and personality disorders. Psychiatr Clin North Am 1990; 13: 661-684 [F]
226. Brooks RB, Baltazar PL, McDowell DE, Munjack DJ, Bruns JR: Personality disorders co-occurring with panic disorder with agoraphobia. J Personality Disorders 1991; 5: 328-336 [D]
227. Pollack MH, Otto MW, Rosenbaum JF, Sachs GS: Personality disorders in patients with panic disorder: association with childhood anxiety disorders, early trauma, comorbidity, and chronicity. Compr Psychiatry 1992; 33: 78-83 [C]
228. Reich JH: DSM-III personality disorders and the outcome of treated panic disorder. Am J Psychiatry 1988; 145: 1149-1152 [B]
229. Reich J, Troughton E: Frequency of DSM-III personality disorders in patients with panic disorder: comparison with psychiatric and normal control subjects. Psychiatry Res 1988; 26: 89-100 [A]
230. Reich JH, Vasile RG: Effect of personality disorders on the treatment outcome of axis I conditions: an update. J Nerv Ment Dis 1993; 181: 475-484 [F]
231. Green M, Curtis GC: Personality disorders and panic patients: response to termination of antipanic medication. J Personality Disorders 1988; 2: 303-314 [B]
232. Chambless DL, Renneberg B, Goldstein A, Gracely EJ: MCMI-diagnosed personality disorders among agoraphobic outpatients: prevalence and relationship of severity and treatment outcome. J Anxiety Disorders 1992; 6: 195-211 [D]
233. Marchand A, Goyer LR, Mainguy N: L'impact de la presence de troubles de la personnalité sur la réponse au traitement behavioral-cognitif du trouble panique avec agoraphobie. Science et Comportement 1992; 22: 149-161 [B]
234. Black DW, Wesner RB, Gabel J, Bowers W, Monahan P: Predictors of short-term treatment response in 66 patients with panic disorder. J Affect Disord 1994; 30: 233-241 [A]
235. Dreessen L, Arntz A, Luttels C, Sallaerts S: Personality disorders do not influence the results of cognitive behavioral therapies for anxiety disorders. Compr Psychiatry 1994; 35: 265-274 [B]
236. Keijsers GPJ, Hoogduin CAL, Schapp CPDR: Prognostic factors in the behavioral treatment of panic disorder with and without agoraphobia. Behavior Therapy 1994; 25: 689-708 [B]
237. Karajgi B, Rifkin A, Doddi S, Kolli R: The prevalence of anxiety disorders in patients with chronic obstructive pulmonary disease. Am J Psychiatry 1990; 147: 200-201 [D]
238. Kaplan DS, Masand PS, Gupta S: The relationship of irritable bowel syndrome (IBS) and panic disorder. Ann Clin Psychiatry 1996; 8: 81-88 [D]
239. Lydiard RB, Greenwald S, Weissman MM, Johnson J, Drossman DA, Ballenger JC: Panic disorder and gastrointestinal symptoms: findings from the NIMH Epidemiologie Catchment Area project. Am J Psychiatry 1994; 151: 64-70 [E]
240. Kawachi I, Colditz GA, Ascherio A, Rimm E, Giovannucci E, Stampfer MJ, Willett WC: Prospective study of phobic anxiety and risk of coronary heart disease in men. Circulation 1994; 89: 1992-1997 [C]
241. American Academy of Child and Adolescent Psychiatry: Practice Parameters for the Assessment and Treatment of Children and Adolescents With Anxiety Disorders. J Am Acad Child Adolesc Psychiatry 1997; 36(10 suppl): 69S-84S [G]
242. Black B: Separation anxiety disorder and panic disorder, in Anxiety Disorders in Children and Adolescents. Edited by March J. New York, Guilford Press, 1995, pp 212-234 [G]
243. Black B, Robbins D: Panic disorder in children and adolescents. J Am Acad Child Adolesc Psychiatry 1990; 29: 36-44 [F]
244. Kearney CA, Silverman WK; The panic disorder controversy continues. J Am Acad Child Adolesc Psychiatry 1991; 30: 852-853 [G]
245. Kearney CA, Silverman WK: Let's not push the "panic" button: a critical analysis of panic and panic disorder in adolescents. Clin Psychol Rev 1992; 12: 293-305 [E]
246. Whitaker A, Johnson J, Shaffer D, Rapoport JL, Kalikow K, Walsh BT, Davies M, Braiman S, Dolinsky A: Uncommon troubles in young people: prevalence estimates of selected psychiatric disorders in a nonreferred adolescent population. Arch Gen Psychiatry 1990; 47: 487-496 [D]
247. Hayward C, Killen JD, Hammer LD, Lift IF, Wilson DM, Simmonds B, Taylor CB: Pubertal stage and panic attack history in sixth- and seventh-grade girls. Am J Psychiatry 1992; 149: 1239-1243 [D]
248. Curry J, Murphy L: Comorbidity of anxiety disorders, in Anxiety Disorders in Children and Adolescents. Edited by March J. New York, Guilford Press, 1995, pp 301-317 [G]
249. Kovacs M, Feinberg TL, Crouse-Novak MA, Paulauskas SL, Finkelstein R: Depressive disorders in childhood, I: a longitudinal prospective study of characteristics and recovery. Arch Gen Psychiatry 1984; 41: 229-237 [B]
250. Bernstein GA: Comorbidity and severity of anxiety and depressive disorders in a clinic sample. J Am Acad Child Adolesc Psychiatry 1991; 30: 43-50 [C]
251. Last CG, Francis G, Hersen M, Kazdin AE, Strauss CC: Separation anxiety and school phobia: a comparison using DSM-III criteria. Am J Psychiatry 1987; 144: 653-657 [D]
252. Last CG, Strauss CC: School refusal in anxiety-disordered children and adolescents. J Am Acad Child Adolesc Psychiatry 1990; 29: 31-35 [D]
253. Gittelman-Klein R, Klein DF: School phobia: diagnostic considerations in the light of imipramine effects. J Nerv Ment Dis 1973; 156: 199-215 [B]
254. Ollendick TH: Cognitive behavioral treatment of panic disorder and agoraphobia in adolescents: a multiple baseline design analysis. Behavior Therapy 1995; 26: 517-531 [E]
255. Barlow DH: Effectiveness of behavior treatment for panic disorder with and without agoraphobia, in Treatment of Panic Disorder: A Consensus Development Conference. Edited by Wolfe BE, Maser JD. Washington, DC, American Psychiatric Press, 1994, pp 105-120 [G]
256. Ballenger JC, Carek DJ, Steele JJ, Cornish-McTighe D: Three cases of panic disorder with agoraphobia in children. Am J Psychiatry 1989; 146: 922-924 [G]
257. Biederman J: Clonazepam in the treatment of prepubertal children with panic-like symptoms. J Clin Psychiatry 1987;48(Oct suppl): 38-42 [B]
258. Birmaher B, Waterman GS, Ryan N, Cully M: Fluoxetine for childhood anxiety disorders. J Am Acad Child Adolesc Psychiatry 1994; 33: 993-999 [B]
259. Kutcher SP, MacKenzie S: Successful clonazepam treatment of adolescents with panic disorder. J Clin Psychopharmacol 1988; 8: 299-301 [G]
260. Blazer D, George LK, Hughes D: The epidemiology of anxiety disorders: an age comparison, in Anxiety and the Elderly: Treatment and Research. Edited by Salzman C, Lebowitz BD. New York, Springer, 1991, pp 17-30 [G]
261. Eaton WW, Dryman A, Weissman MM: Panic and phobia, in Psychiatric Disorders in America. Edited by Robins LN, Regier DA. New York, Free Press, 1991, pp 155-179 [G]
262. Altshuler LL, Cohen L, Szuba MP, Burt VK, Gitlin M, Mintz J: Pharmacologie management of psychiatric illness during pregnancy: dilemmas and guidelines. Am J Psychiatry 1996; 153: 592-606 [F]
263. Regier DA, Myers JK, Kramer M, Robins LN, Blazer DG, Hough RL, Eaton WW, Locke BZ: The NIMH Epidemiologie Catchment Area program: historical context, major objectives, and study population characteristics. Arch Gen Psychiatry 1984; 41: 934-941 [G]
264. Kessler RC, McGonagle K A, Zhao S, Nelson CB, Hughes M, Eshleman S, Wittchen HU, Kendler KS: Lifetime and 12 month prevalence of DSM-III-R psychiatric disorders in the United States: results from the National Comorbidity Survey. Arch Gen Psychiatry 1994; 51: 8-19 [C]
265. Blazer D, George LK, Landerman R, Pennybacker M, Melville ML, Woodbury M, Manton KG, Jordan K, Locke B; Psychiatric disorders: a rural/urban comparison. Arch Gen Psychiatry 1985; 42: 651-656; correction 1986; 43: 1142 [G]
266. Horwath E, Johnson J, Hornig CD: Epidemiology of panic disorder in African-Americans. Am J Psychiatry 1993; 150: 465-469 [D]
267. Paradis CM, Friedman S, Lazar RM, Grubea J, Kesselman M: Use of a structured interview to diagnose anxiety disorders in a minority population. Hosp Community Psychiatry 1992; 43: 61-64 [G]
268. Bell CC, Shakoor B, Thompson B, Dew D, Hughley E, Mays R, Shorter-Gooden K: Prevalence of isolated sleep paralysis in black subjects. J Natl Med Assoc 1984; 76: 501-508 [D]
269. Neal AM, Smucker WD: The presence of panic disorder among African American hypertensives: a pilot study. J Black Psychol 1994; 20: 29-35 [D]
270. Bell CC, Hildreth CJ, Jenkins EJ, Carter C: The relationship of isolated sleep paralysis and panic disorder to hypertension. J Natl Med Assoc 1988; 80: 289-294 [D]
271. Brown C, Schulberg HC, Madonia MJ: Clinical presentations of major depression by African Americans and whites in primary medical care practice. J Affect Disord 1996;41: 181-191 [A]
272. Neighbors HW: Seeking help for personal problems: black Americans' use of health and mental health services. Community Mem Health J 1985; 21: 156-166 [D]
273. Cooper-Patrick L, Crum RM, Ford DE: Characteristics of patients with major depression who received care in general medical and specialty mental health settings. Med Care 1994; 32: 15-24 [E]